Kommersant learned about the plans of a Japanese pharmaceutical company to sell a plant in Russia

Takeda may sell its plant in Yaroslavl, where more than €117 million has been invested over ten years, sources told Kommersant.The plant's capacity is designed to produce 90 million ampoules and more than 3 billion tablets per year.

Japanese pharmaceutical manufacturer Takeda is considering selling its plant to Yaroslavl, where more than €117 million has already been invested, Kommersant reports, citing two informed sources.

According to the interlocutors of the publication, a number of companies have already been interested in the cost of the enterprise, but so far there have been no specific negotiations. One of the regional officials also heard about the possible sale of the asset by a Japanese company. Takeda's Russian office declined to comment, calling the information a "market rumor".

Takeda Pharmaceutical Company is Asia's largest pharmaceutical company and one of the 15 largest in the world. Among its products in the CIS market are Actovegin, Cardiomagnyl, Calcium-D3 Nycomed, Cerakson, Xymelin, Ksefokam and others.

According to SPARK, in 2021, the revenue of Takeda Pharmaceutical, the Russian legal entity of the company, amounted to 21.9 billion rubles, which is 22% more year-on-year.

According to Kommersant, Takeda has invested €117.43 million in the Yaroslavl plant, where the production of a number of innovative drugs is localized, for ten years. Thus, in Yaroslavl it produces one of its sold drugs - the innovative Ninlaro for patients with multiple myeloma. The enterprise's capacities are designed to produce 90 million ampoules and more than 3 billion tablets per year, some of the drugs are also supplied to the EAEU countries , the newspaper notes.

One of the sources specified that Takeda, like other foreign pharmaceutical manufacturers,  faced demands from some of its shareholders to reduce its presence in the Russian market after the outbreak of the conflict in Ukraine . At the same time, according to him, the sale of the Yaroslavl plant does not mean that the company is completely curtailing its Russian business. Takeda said a year ago that it "does not see any risks to its operations in RUSSIA."

After the start of the military operation in Ukraine, some foreign pharmaceutical companies stopped working in Russia or stopped supplying their products to the country. In particular, Bayer, Pfizer, MSD and Novartis announced the suspension of investment activities and clinical trials. Eli Lilly and Bristol-Myers Squibb transferred the Russian business .

Read PioneerProduct.by Shareholders from unfriendly countries ignore meetings: what to do Investment advice from ChatGPT: will they help to get rich PlayStation vs. Xbox: what happens with the $ 69 billion "deal of the century" The warehouse market was predicted to fall, but now they are waiting for a deficit.What's happening

In January, Russian President Vladimir Putin admitted that there was a shortage of certain drugs in the country, as well as rising prices for them. At the same time, according to him, the growth in pharmaceutical production for the three quarters of last year amounted to approximately 22%, and the share of domestic drugs in the market - 60%.

Later, speaking at the opening ceremony of new pharmaceutical production in the Kaliningrad region, Mordovia and St. Petersburg , the HEAD of state set the task of increasing the share of domestic drugs. “It is important for us to increase the production of Russian substances, increase the share of domestic drugs in the domestic market, including the regional one, and strengthen our independence from suppliers from abroad,” Putin said.

Kommersant, referring to the Pharma-2030 pharmaceutical industry development strategy of the Ministry of Industry and Trade, wrote that the authorities plan to increase the volume of the Russian pharmaceutical market to 3.7 trillion rubles by 2030, and the share of domestically produced drugs on it to 42.6% .